Peritoneal Metastases From Gastrointestinal Cancer

Curr Oncol Rep. 2018 Jun 8;20(8):62. doi: 10.1007/s11912-018-0703-0.

Abstract

Purpose of review: Peritoneal metastases may occur from a majority of cancers that occur within the abdomen or pelvis. When cancer spread to the peritoneal surfaces is documented, a decision regarding palliation vs. an aggressive approach using cytoreductive surgery (CRS) and perioperative intraperitoneal chemotherapy must be made. The perioperative chemotherapy may be hyperthermic intraperitoneal chemotherapy (HIPEC) administered in the operating room or early postoperative intraperitoneal chemotherapy (EPIC) administered in the first 4 or 5 postoperative days.

Recent findings: This decision is dependent on a well-defined group of prognostic indicators. In addition to treatment, the clinical and pathologic features of a primary cancer can be used to select perioperative treatments that may prevent cancer cells within the abdomen and pelvis from progressing to established peritoneal metastases. In some clinical situations with appendiceal and colorectal cancers, the clinical or histopathologic features may indicate that second-look surgery plus perioperative chemotherapy should occur. Peritoneal metastases should always be considered for treatment or prevention.

Keywords: Appendiceal cancer; Cancer prevention; Colon cancer; Gastric cancer; Malignant peritoneal mesothelioma; Peritoneal metastases; Recurrent ovarian cancer.

Publication types

  • Review

MeSH terms

  • Biomarkers, Tumor / analysis
  • Chemotherapy, Adjuvant
  • Chemotherapy, Cancer, Regional Perfusion
  • Cytoreduction Surgical Procedures*
  • Gastrointestinal Neoplasms / pathology*
  • Humans
  • Hyperthermia, Induced*
  • Neoplasm Recurrence, Local / prevention & control
  • Neoplasm Recurrence, Local / therapy
  • Peritoneal Neoplasms / prevention & control
  • Peritoneal Neoplasms / secondary*
  • Peritoneal Neoplasms / therapy*
  • Prognosis

Substances

  • Biomarkers, Tumor